Manhattan BioSolutions Inc., a U.S.-based biotechnology company, has entered into an assessment and potential licensing agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a Chinese biopharmaceutical firm. Through this agreement, Manhattan BioSolutions is poised to gain access to a range of antibodies targeting a novel tumor antigen that is notably overexpressed in multiple solid tumor types, including those that are treatment-resistant, aggressive, and metastatic.
The antigen in question is an ovarian-specific developmental signaling protein typically found in ovary, testis, and adrenal tissues, but it is overexpressed in various cancers such as ovarian, endometrial, cervical, renal, hepatic, colorectal, and lung tumors. The agreement grants Manhattan BioSolutions access to a diverse panel of lead fully-human monoclonal antibodies generated through Biocytogen’s cutting-edge RenMab and RenLite platforms.
Manhattan BioSolutions will conduct a thorough evaluation of these antibodies, assessing binding affinity, internalization, species cross-reactivity, and other developability parameters in cellular and biochemical assays. This evaluation aims to determine the suitability of these antibodies for integration into antibody-based therapeutic modalities that carry Manhattan BioSolutions’ proprietary RNA targeting payloads. The most promising candidates identified through this process may be selected for further development into precision medicines, potentially offering new treatment options for chemoresistant, aggressive, or metastatic tumors.- Flcube.com
